RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250, Maintains Sector Perform Rating.
RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250 Read Post »
RBC Capital Cuts Price Target on Moderna (NASDAQ:MRNA) to $190 From $200, Maintains Outperform Rating.
RBC Capital Cuts Price Target on Moderna (NASDAQ:MRNA) to $190 From $200 Read Post »
TD Cowen analyst Tyler Van Buren downgrades Moderna (NASDAQ:MRNA) from Outperform to Market Perform and lowers the price target from $145 to $125.
TD Cowen lowers Moderna (NASDAQ:MRNA) price target from $145 to $125 Read Post »
RBC Capital Boosts Price Target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $820 From $818, Keeps Sector Perform Rating.
Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q2 non-GAAP earnings of $10.24 diluted share, up from $9.77 a year earlier. Analysts polled by Capital IQ expected $9.90. Revenue for the quarter ended June 30 was $3.16 billion, up from $2.86 billion a year earlier. Analysts surveyed by Capital IQ expected $3.02 billion. The company now anticipates 2023 capital expenditures in the range of $760 million to $830 million versus its previous guidance of $800 million to $900 million.
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 Non-GAAP Earnings, Revenue Advance Read Post »
Amgen (NASDAQ:AMGN) reported Q2 non-GAAP diluted earnings of $5.00, up from $4.65 a year earlier. Analysts surveyed by Capital IQ expected $4.49. Revenue for the quarter ended June 30 was $6.99 billion, up from $6.59 billion a year earlier. Analysts surveyed by Capital IQ expected $6.68 billion. The company said it now expects fiscal 2023 non-GAAP diluted earnings of $17.80 to $18.80 per share, up from its prior guidance of $17.60 to $18.70. Analysts surveyed by Capital IQ are expecting $17.70. Revenue for the year is now projected to be in the range of $26.60 billion to $27.40 billion, the company said. That compares with its prior guidance of $26.20 billion to $27.30 billion. Analysts surveyed by Capital IQ are looking for $27.32 billion. The company also said it expects share buybacks not to exceed $500 million.
Amgen (NASDAQ:AMGN) Q2 Non-GAAP Earnings, Revenue Increase; 2023 Guidance Boosted Read Post »
Raymond James analyst John Ransom maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $90 to $85.
Raymond James lowers CVS Health (NYSE:CVS) price target from $90 to $85 Read Post »
Gilead Sciences (NASDAQ:GILD) reported Q2 non-GAAP diluted earnings of $1.34, down from $1.58 a year earlier. Analysts surveyed by Capital IQ expected $1.64. Revenue for the quarter ended June 30 was $6.60 billion, up from $6.26 billion a year earlier. Analysts surveyed by Capital IQ expected $6.45 billion. The company said it expects full-year 2023 non-GAAP diluted EPS of $6.45 to $6.80, down from the previous outlook of $6.60 to $7. Analysts surveyed by Capital IQ expect $6.73. The company expects product sales for the year of $26.3 billion to $26.7 billion, compared with previous outlook of $26.0 billion to $26.5 billion. Gilead said its board maintained a quarterly dividend of $0.75 per share, payable on Sept. 28 to stockholders of record on Sept. 15.
Gilead Sciences (NASDAQ:GILD) Q2 Non-GAAP Earnings, Revenue Fall;FY2023 Outlook issued Read Post »
Amgen (NASDAQ:AMGN) Q2 EPS $5.00 Vs. $4.65 a Year Ago, Beats the FactSet Consensus $4.49。
Amgen (NASDAQ:AMGN) Q2 EPS $5.00, Beats the FactSet Consensus $4.49 Read Post »
Amgen (NASDAQ:AMGN) Guides For 2023 EPS of $17.80-$18.80 on Revenue of $26.6-$27.4 Billion, Vs CIQ Analyst Consensus of $17.70/Share on Revenue of $27.3 Billion。
Amgen (NASDAQ:AMGN) Guides For 2023 EPS of $17.80-$18.80 Read Post »
UBS Adjusts CVS Health (NYSE:CVS) Price Target to $92 From $94, Maintains Buy Rating.
UBS Adjusts CVS Health (NYSE:CVS) Price Target to $92 From $94 Read Post »
Barclays analyst Steve Valiquette maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $89 to $86.
Barclays lowers CVS Health (NYSE:CVS) price target from $89 to $86 Read Post »